Sex Differences in Treatment Expectations, Satisfaction and Tolerance After Switching to CT-P17, an Adalimumab Biosimilar: A Post Hoc Analysis of the YU-MATTER Study.

Rheumatol Ther · 2026 · PMC13198574 · PMID 41838366

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The cumulative duration of adalimumab also showed a trend towards being longer in men than women (mean ± SD 60.4 ± 41.1 vs 54.8 ± 46.1 months), but the difference was not statistically significant ( p = 0.112).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.